BeOne lifts full-year outlook after BRUKINSA pushes quarterly sales to $1.4bn
The company's third-quarter revenue reached $1.9bn, driven by its BTK inhibitor, and it took a $22m charge tied to a biosimilar it is no longer promoting.
BeOne Medicines said on 5 November that revenue for the third quarter of 2026 totalled $1.9bn, up 34% year on year. Its BTK inhibitor BRUKINSA (zanubrutinib) generated $1.4bn of that, or roughly three-quarters of the total on the rounded figures reported.
Alongside the results, the company moved its expectations for the full year up. It now expects 2026 revenue of $6.9bn to $7.0bn and has also raised its operating income guidance. The material available to us does not include the new operating income range or the earlier guidance, so the size of the upgrade cannot be measured here.
BeOne also booked a $22m impairment charge connected to its decision to end promotional activity for POBEVCY. The material reviewed gives no reason for the move and does not say whether the product will stay on the market or what the company plans for it.
The figures show a business that depends heavily on a single product. Further detail on the guidance and on POBEVCY will be in the company's full results release, which we have not seen.
Why it matters
- BRUKINSA accounts for about three-quarters of BeOne's quarterly revenue, so the group's performance rests largely on one BTK inhibitor.
- A full-year revenue range of $6.9bn to $7.0bn, with higher operating income guidance, signals management confidence, but the prior ranges are not available for comparison.
- The $22m impairment on POBEVCY is small beside the quarterly revenue, but the reasons for ending its promotion and the product's future have not been disclosed.
Company's press release (SEC filing): BeOne Medicines Ltd. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
